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      Amendments from Version 1
As recommended by Dr Lee, we have:
1. clarified that colomycin 2MU thrice daily was given 
intravenously alongside intravenous Tazocin
2. clarified the location (home/hospital) for all treatment courses
3. clarified that the subject was also using nebulised dornase 
alfa throughout all treatment courses
4. provided objective adherence (I-neb data) during the dual 
nebulised antibiotics courses
As recommended by Drs Frost and Nazareth, we have:
1. mentioned the 2014 randomised cross-over trial of inhaled 
tobramycin in the introduction
2. clarified that “typically one inhaled antibiotic is used as a 
time” referred to chronic setting
3. described organisms isolated from her sputum in the 
prior-year, follow-up year and subsequent year (this was also 
recommended by Dr Liou)
4. clarified the location (home/hospital) for all treatment courses
5. clarified the use of adjunctive therapies
As recommended by Dr Liou, we have:
1. clarified which treatment courses were specifically for acute 
exacerbation - the 1st dual nebulised antibiotics course was for 
acute exacerbation (subject was symptomatic although %FEV1 
was relatively stable) and the 3rd intravenous antibiotics course 
was for acute exacerbation (4% absolute decline in FEV1 from 
previous although there was no clear symptoms)
2. iterated the sentence in 2nd paragraph of “case report” to 
clarify the more intensive treatment during the follow-up year
3. provided more detailed results for sputum cultures
4. provided in generic name with first use of trademarked 
names for nebulised antibiotics, and only using generic name 
for intravenous antibiotics
We have explained in our response to Dr Liou’s comments that 
we felt adequate history has been provided (especially in terms 
of age and genotype), and that we have already provided a 
gold-standard adherence measure in the form of adherence 
data captured using I-neb (a data logging nebuliser).
See referee reports
REVISED
There is scant research on using inhaled antibiotics to treat 
exacerbations. A Cochrane review in 2012 found only four 
relevant studies, with inadequate sample sizes to demonstrate 
efficacy6. Subsequently, a randomised cross-over trial among 
20 adults with CF and pulmonary exacerbation in 2014 demon-
strated longer time to next exacerbation with nebulised compared 
to intravenous tobramycin (all participants received intravenous 
colistin as the second antibiotic)7. A large observational study in 
North America found that ~24% of exacerbations are treated with 
inhaled antibiotics8. Inhaled antibiotics have several advantages. 
Systemic adverse effects e.g. allergic reactions, gastrointestinal 
manifestations, ototoxicity and renal failure are common with 
intravenous antibiotics9,10 but rare with inhaled antibiotics11. 
Higher antibiotic concentrations within the airways are achieved 
via inhaled route, which may be beneficial in overcoming 
resistance12. Inhaled route also overcomes difficulties associated 
with venous access.
For long-term suppressive therapy, typically one inhaled 
antibiotic is used at a time, and someone on multiple inhaled 
antibiotics would alternate between those antibiotics11. Of the five 
existing trials looking at inhaled antibiotics for acute exacerba-
tion, only one study with 18 participants concomitantly administed 
two inhaled antibiotics (tobramycin and carbenicillin)6. Yet dual 
inhaled antibiotics (i.e. concomitant use of two different inhaled 
antibiotics) may have synergistic effect, thus achieve better 
results. We report on an adult with CF and chronic Psae infec-
tion who achieved good results when treating exacerbations using 
dual inhaled antibiotics.
Case report
A Caucasian female in her early thirties with F508del/Class I 
mutation, pancreatic insufficiency and CF related diabetes also 
fulfilled the Leeds criteria13 for chronic Psae infection. Only Psae 
(Liverpool epidemic strain sensitive only to colistin) was cultured 
from all 12 sputum samples in the previous year. Despite high 
objective adherence to nebulised dornase alfa 2.5mg once daily and 
alternating colistin (Promixin®) 1megaunit twice daily/tobramycin 
(TOBI®) 300mg twice daily (82.9% two years ago, 96.3% in 
the previous year; measured with an I-neb®), stable BMI around 
23.1 and reasonable glycaemic control (HbA1c 47 in month 1 
of the follow-up period), there was a trend of declining %FEV
1
. 
Her annual best FEV
1
 was 47%, 44% and 42% over the previous 
three years. There was no evidence of allergic bronchopulmonary 




In month one, Promixin® was also switched to nebulised 
Aztreonam (AZLI®) 75mg thrice daily. She had two courses 
(28 days) of intravenous antibiotics throughout the previous 
year. She agreed to three-monthly intravenous antibiotics in the 
follow-up year to try halt the FEV
1
 decline. She had 14 days of 
home intravenous piperacillin/tazobactam 4.5g thrice daily 
and intravenous colistin 2megaunit thrice daily in month one 
(%FEV
1
 improved from 38% to 40%), and again in month 4 
(%FEV
1
 declined from 40% to 38%).
Introduction
Cystic fibrosis (CF) is a genetic condition whereby ~80% of 
mortalities are primarily due to lung disease1. People with CF 
are prone to recurrent respiratory infections (termed ‘pulmonary 
exacerbations’), which leads to progressive lung damage and 
respiratory failure2. This is especially so after Pseudomonas 
aeruginosa (Psae) is acquired3.
Although there is a lack of evidence for best practice in treating 
exacerbations among adults with CF and chronic Psae infection4, 
two weeks of dual intravenous antibiotics are generally used for 
synergistic effect4,5. The European CF Society recommend against 
using inhaled antibiotics to treat exacerbations, due to concerns 
that increased mucus plugs during exacerbations may prevent 
antibiotics from reaching smaller airways5.
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She felt less well with increased sputum volume and dyspnoea 
at the start of month six. Her %FEV
1
 was 39%. She agreed to 
try 14 days of concomitant nebulised AZLI® 75mg thrice daily and 
TOBI® 300mg twice daily at home (nebulised dornase alfa was 
continued) as treatment for acute exacerbation. She used 69/70 
(98.6%) of her nebuliser doses over the 14 days (note that 
TOBI® twice daily = 4 doses via I-neb® and AZLI® could not 
be administered via I-neb®). Her %FEV
1
 improved to 45% at 
day 7 and 44% at day 14. Her symptoms resolved by day 14.
She felt well but her %FEV
1
 declined to 39% during her next 
clinic review at the end of month seven. She went on another 
14-day course of home intravenous piperacillin/tazobactam 4.5g 
thrice daily and intravenous colostin 2megaunit thrice daily as 
treatment for acute exacerbation. At day 14, her %FEV
1
 remained 
39%. Another 14-day course of home concomitant nebulised 
AZLI® and TOBI® was started in month 8 (nebulised dornase alfa 
was continued). She used 66/70 (94.3%) of her nebuliser doses 
over the 14 days (note that TOBI® twice daily = 4 doses via 
I-neb® and AZLI® could not be administered via I-neb®). Her 
%FEV
1
 improved to 41% at day 7 and day 14, despite develop-
ing viral coryzal symptoms at day 12. With 14 days of hospital 
IV piperacillin/tazobactam 4.5g thrice daily and intravenous 
tobramycin 480mg once daily in month 11, her %FEV
1
 improved 
from 39% at day 1 to 41% at day 14. She received intensive 
physiotherapy during her in-patient stay in month 11 which may 
contribute to some of the %FEV
1
 improvement but received no 
other adjunctive therapies (e.g. corticosteroid) during all treat-
ment courses. All her inhaled therapies were continued during dual 
intravenous antibiotic courses.
During the follow-up year, only Psae (Liverpool epidemic 
strain sensitive only to colistin) was cultured from all eight spu-
tum samples. During the subsequent year, only Psae (Liverpool 
epidemic strain sensitive only to colistin) was cultured from all 
nine sputum samples.
Discussion
In this case, %FEV
1
 improvement following acute treatment 
of exacerbations with dual inhaled antibiotics at home (mean 
3.5% over two courses) was somewhat higher than with dual 
intravenous antibiotics (mean 0.5% over four courses), despite 
similar baseline %FEV
1
 and one of the intravenous antibiotics 
courses was delivered in hospital. The %FEV
1
 improvement also 
occurred despite severe background lung disease (high resolution 




Although she reported symptomatic improvement during her 
first dual inhaled antibiotics course, we did not formally measure 
symptomatic responses to treatments with a validated tool. 
The sample size is too small for null hypothesis significance 
testing, and regression to the mean is potentially a threat to our 
results. Our results are nonetheless intriguing and suggest that 
dual inhaled antibiotics could potentially have a role in treating 
exacerbations among adults with CF and chronic Psae infec-
tion. With the increasing number of inhaled anti-pseudomonal 
antibiotics available, e.g. nebulised levofloxacin14, different 
combinations of concomitant inhaled antibiotics can be used in 
the future for synergistic effect.
Like all medications, there are adverse events associated 
with inhaled antibiotics. There is a case report of acute respiratory 
distress syndrome potentially due to inhaled colistin15. However, 
localised adverse events with inhaled antibiotics are usually mild, 
e.g. bronchoconstriction which tends to resolve spontaneously 
within hours or can be controlled by pre-dosing with nebulised 
bronchodilator11.
High adherence to inhaled therapies probably contributed to the 
good clinical response from dual inhaled antibiotics observed 
in this case. Real-world adherence with long-term inhaled 
antibiotics among adults with CF is only 35–50%16,17. Some-
one who is already struggling with a single inhaled antibiotic is 
unlikely to cope with dual inhaled antibiotics, thus may derive 
less benefit. However, adherence to short-term drug regimen tends 
to be higher18. Adults with CF might be able to summon adequate 
self-regulation during a 14-day dual antibiotics course to really 
focus on their nebuliser use19.
In conclusion, the %FEV
1
 improvements observed in this case 
report provide anecdotal evidence that dual inhaled antibiotics 
could potentially be a treatment option for exacerbations among 
adults with CF and chronic Psae infection. Given the lack of good 
quality evidence regarding optimum exacerbations treatments and 
the theoretical advantages of using inhaled antibiotics, this warrants 
further investigations.
Consent
Written informed consent for publication of her clinical details 
was obtained from the patient.
Data availability
No data is associated with this article.
Competing interests
No competing interests were disclosed.
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